Aloysius Mark Madhok

Dr. Aloysius Mark Madhok

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Pancreatology
Verified
Journal Article
Closed access
AMAloysius Mark Madhok
Aloysius Mark Madhok
ATAshwin Thatti
Ashwin Thatti
AGAnjalika Gupta
Anjalika Gupta
NSNishant Sharma
Nishant Sharma
PBPardeep Bansal
Pardeep Bansal
Hemant GoyalHemant Goyal
Hemant Goyal

Verified
Journal Article
Open access
PDF file
HAHunain Aslam
Hunain Aslam
FOFouzia Oza
Fouzia Oza
KAKhalid Ahmed
Khalid Ahmed
JKJonathan J Kopel
Jonathan J Kopel
AMAloysius Mark Madhok
Aloysius Mark Madhok
Hemant GoyalHemant Goyal
Hemant Goyal
Liver disease is one of the leading public health problems faced by healthcare practitioners regularly. As such, there has been a search for an inexpensive, readily available, non-invasive marker to aid in monitoring and prognosticating hepatic disorders. Recently, red blood cell distribution width (RDW) has been found to be associated with various inflammatory conditions with implications for its use as a potential marker for assessing disease progression and prognosis in multiple conditions. Multiple factors effect red blood cell production whereby a dysfunction in any process can lead to anisocytosis. Furthermore, a chronic inflammatory state leads to increased oxidative stress and produces inflammatory cytokines causing dysregulation and increased intracellular uptake and use of both iron and vitamin B12, which leads to a reduction in erythropoiesis causing an increase in RDW. This literature review reviews in-depth pathophysiology that may lead to an increase in RDW and its potential correlation with chronic liver diseases, including hepatitis B, hepatitis C, hepatitis E, non-alcoholic fatty liver disease, autoimmune hepatitis, primary biliary cirrhosis, and hepatocellular carcinoma. In our review, we examine the use of RDW as a prognostic and predictive marker for hepatic injury and chronic liver disease.

6 November 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSonali Sachdeva
Sonali Sachdeva
HKHarshwardhan Khandait
Harshwardhan Khandait
JKJonathan J Kopel
Jonathan J Kopel
AMAloysius Mark Madhok
Aloysius Mark Madhok
RDRupak Desai
Rupak Desai
Hemant GoyalHemant Goyal
Hemant Goyal
The earliest evidence from China suggested that COVID-19 patients are even more vulnerable to succumbing from complications in the presence of a multimorbid status, including metabolic syndrome. Due to ongoing metabolic abnormalities, non-alcoholic fatty liver disease (NAFLD) appears to be a potential risk factor for contracting SARS-CoV-2 infection and developing related complications. This is because of the interplay of chronically active inflammatory pathways in NAFLD- and COVID-19-associated acute cytokine storm. The risk of severe disease could also be attributed to compromised liver function as a result of NAFLD. We systematically reviewed current literature to ascertain the relationship between NAFLD and severe COVID-19, independent of obesity, which is considered the major factor risk factor for both NAFLD and COVID-19. We found that NAFLD is a predictor of severe COVID-19, even after adjusting for the presence of obesity (OR 2.358; 95% CI: 1.902–2.923, p < 0.001).

9 March 2022 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
ADAnasua Deb
Anasua Deb
APAbhilash Perisetti
Abhilash Perisetti
Hemant GoyalHemant Goyal
Hemant Goyal
AMAloysius Mark Madhok
Aloysius Mark Madhok
SSSonali Sachdeva
Sonali Sachdeva
NTNirav Thosani
Nirav Thosani

29 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAloysius Mark Madhok
Aloysius Mark Madhok
Hemant GoyalHemant Goyal
Hemant Goyal
NSNiraj J. Shah
Niraj J. Shah
KPKumar Pallav
Kumar Pallav
NJNimy John
Nimy John
BTBenjamin Tharian
Benjamin Tharian
Introduction: We aimed to assess the impact of socio-economic determinants of health (SEDH) on survival disparities within and between the ethnic groups of young-onset (<50 years age) colorectal adenocarcinoma patients. Patients and Methods: Surveillance, epidemiology, and end results (SEER) registry was used to identify colorectal adenocarcinoma patients aged between 25–49 years from 2012 and 2016. Survival analysis was performed using the Kaplan–Meir method. Cox proportional hazards model was used to determine the hazard effect of SEDH. American community survey (ACS) data 2012–2016 were used to analyze the impact of high school education, immigration status, poverty, household income, employment, marital status, and insurance type. Results: A total of 17,145 young-onset colorectal adenocarcinoma patients were studied. Hispanic (H) = 2874, Non-Hispanic American Indian/Alaskan Native (NHAIAN) = 164, Non-Hispanic Asian Pacific Islander (NHAPI) = 1676, Non-Hispanic black (NHB) = 2305, Non-Hispanic white (NHW) = 10,126. Overall cancer-specific survival was, at 5 years, 69 m. NHB (65.58 m) and NHAIAN (65.67 m) experienced worse survival compared with NHW (70.11 m), NHAPI (68.7), and H (68.31). High school education conferred improved cancer-specific survival significantly with NHAPI, NHB, and NHW but not with H and NHAIAN. Poverty lowered and high school education improved cancer-specific survival (CSS) in NHB, NHW, and NHAPI. Unemployment was associated with lowered CSS in H and NAPI. Lower income below the median negatively impacted survival among H, NHAPI NHB, and NHW. Recent immigration within the last 12 months lowered CSS survival in NHW. Commercial health insurance compared with government insurance conferred improved CSS in all groups. Conclusions: Survival disparities were found among all races with young-onset colorectal adenocarcinoma. The pattern of SEDH influencing survival was unique to each race. Overall higher income levels, high school education, private insurance, and marital status appeared to be independent factors conferring favorable survival found on multivariate analysis.

9 April 2022 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
NSNiraj James Shah
Niraj James Shah
AMAloysius Mark Madhok
Aloysius Mark Madhok
EBEldrin Bhanat
Eldrin Bhanat
SGShweta Gupta
Shweta Gupta
GAGanesh Aswath
Ganesh Aswath
Hemant GoyalHemant Goyal
Hemant Goyal
Aim: Gastrointestinal malignant melanoma is a rare mucosal melanoma (MM). Other MM include the respiratory and the genitourinary tract. All mucosal melanomas have a poor prognosis when compared to cutaneous melanomas. Ano-rectal melanomas are by far the most common and most studied gastrointestinal MM. Large-scale clinical data is lacking due to the rarity of the disease. We aim to analyze epidemiology and survival of the Gastrointestinal (G.I.) MM over 45 years using a national database.Methods: The Surveillance, Epidemiology and End Results (SEER) database was queried to identify patients with biopsy-proven G.I. Melanomas. We selected tumor site, intervention, and survival information for oncology codes as per the international classification of diseases. Survival analysis was performed using the SPSS v 27 ® IBM software.Results: Of the 1105 biopsy-proven confirmed cases of primary G.I. melanoma's, 191 (17.3%) received chemotherapy (C.T.), 202 (18.3%) received radiotherapy (R.T.), 63 (5.7%) received both C.T and R.T., while 684 (61.9%) of the population received surgery alone or combined with C.T. and/or R.T. Statistically significant improvement in survival was noted in all treatment strategies that utilized surgery and also when site-specific MM cohorts underwent a surgical approach with or without C.T and/or R.T.Conclusion: This is the most extensive study reporting epidemiological and survival data of treatment strategy outcomes of primary G.I. mucosal melanoma elucidating best overall survival with a management strategy involving surgical intervention.